

Outperform → | Target Price : € 16.0 vs € 13.5

Price (30/04/2025) : € 9.82 | Upside : 63%

Révision


l2/25e 12/26e

EPS

ns 28.1%

# Unique ecosystem to digitise partners creates long-term value

Publication date: 02/05/2025 06:35 Writing date: 30/04/2025 16:44



Sources: ODDO BHF Securities, SIX

Share data			
TPG GY   TPGG.DE			
Market Cap (€m)			200
Enterprise value (€m)			311
Extrema 12 months (€)	7.20	_	10.20
Free Float (%)			20.1

Performance (%)	1m	3m	12m
Absolute	11.6	5.1	28.2
Perf. rel. Country Index	12.9	17.2	35.1
Perf. rel. SDAX	7.9	-2.5	16.3

P&L	12/25e	12/26e	12/27e
Sales (€m)	690	802	839
EBITDA (€m)	69.2	60.0	65.0
Current EBIT (€m)	59.3	50.1	55.0
Attr. net profit (€m)	40.1	27.3	30.8
Adjusted EPS (€)	1.96	1.34	1.51
Dividend (€)	0.00	0.00	0.00
P/E (x) P/B (x) Dividend Yield (%) FCF yield (%) EV/Sales (x) EV/EBITDA (x)	5.0 0.9 0.0 11.7 0.45 4.5	7.3 0.9 0.0 15.2 0.38 5.1	6.5 0.8 0.0 15.1 0.36 4.7
EV/Current EBIT (x)	5.2	6.1	5.6
Gearing (%) Net Debt/EBITDA (x)	51 1.6	46 1.8	39 1.6

## 09/05/2025

23/05/2025 Q1 Results
26/06/2025 Annual General Meeting
22/08/2025 H1 Results

FY Results

Uplift in estimates due to new higher 2025 sales and earnings guidance

In view of the successful business development in O1 2025, the acquisitions made so far in 2025 (such as Joli Closet, Herbertz Group, Lyra Pet), the strong organic growth, and the increased number of partners, TPG has raised its 2025 forecast. GMV (merchandise volume) is expected to increase to € 1.3bn (previously: € 1.2bn, ODDO BHFe € 1.29bn) and net sales to between € 680m and € 700m (previously: € 590m to € 610m, ODDO BHFe 690.5m, css € 650.4m). Due to the positive earnings development and the effect of the implemented cost and efficiency programme (2024-2025), adj. EBITDA will reach € 47m to € 50m (previously: € 40m to € 42m, ODDO BHFe € 48.2m, css € 47.2m) leading to an adj. EBITDA margin (at the mid-point of the guidance range) of 7.0% (+70bp y-o-y, in line with ODDO BHFe, -30bp vs css). The number of partners is expected to rise to more than 16,000 (previously: 15,000, vs 13,521 in 2024) and the number of industries covered to 30 (2024: 25). Considering the earnings contributions of the acquisitions to date and the group's organic growth, TPG is also increasing its medium-term planning (2026). It expects to achieve GMV of € 1.6bn (previously: € 1.5bn, ODDO BHFe € 1.52bn), sales of at least € 820m (previously: € 700m, ODDO BHFe € 802.4m) and an adj. EBITDA margin of between 7% and 10% (unchanged). This compares to our margin forecast of 7.5%. As a result of the new guidance, we have lifted our 2025e to 2026e sales and adj. EBITDA estimates by an average of 20% and 21% respectively.

## 2025 guidance vs estimates

€m	2024	2025 guidance mid-point	у-о-у	2025e	ODDO BHFe vs guidance mid-point
Net sales	525.0	690.0	+31.4%	690.5	+0.1%
Adj. EBITDA	33.2	48.5	+46.1%	48.2	-0.5%
Margin	6.3%	7.0%	+70bp	7.0%	Opb
GMV	903.0	1,300.0	+44.0%	1,291.6	-0.6%
GMV	903.0	1,300.0	+44.0%	1,291.6	-0.6%

Sources: ODDO BHF Securities, company

## Successful e-commerce business drives new target price

With the acquisitions made to date, the M&A pipeline Q2-Q3 2025 (incl. two B2C Niche Platforms and one B2C Optician Platform) and the focus on its cost structure, TPG is in our view well on track to achieve its full year targets. We have used the average of 1) a rolled over DCF (incl. new WACC due to updated market risk premium and risk-free rate metrics) and 2) a valuation approach based on updated peer group multiples to determine our new target price of € 16.0. We confirm our Outperform recommendation.

Klaus Breitenbach (Analyst) +49 (0) 69 718 1011 klaus.breitenbach@oddo-bhf.com

## Page 1/5

## Conflict of interests:

ODDO BHF SCA and/or one of its subsidiaries could be in a conflict of interest situation with one or several of the issuers mentioned in this publication. Please refer to the conflict of interests section at the end of this document.

Thursday, May 1, 2025



Softward         Softward         Softward         Softward         Common Softward         Commo	The Platform Group	Outperform			Price 9.82		
Manual Property		Upside 62.93%	40/00	10/04			40/07
Page   1988							
Medical parabotis   100   1			1.84				1.51
Scheen   1,100			<u>.</u>				
Manuscre of the remoter of green in the content of g	· · · · · · · · · · · · · · · · · · ·						
Name of Polisies American (1999)   127   2012   2							
Martin   1972							
Seminant process   1908   19							
			12/23			12/200	12/2/e
Camerate Non-Residual Manifest         35         20         200         200           Residual Manifest         35         32         33 <th< td=""><td>9 ,</td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	9 ,						
Reture the date of the property of the propert	(*) Reference price (€)			8.26	9.82	9.82	9.82
Manufactor window   1.1   1.2   1.							
France Insection of the State Stat							
Professor   100							
PEÓ         156         5.0         7.3         5.0 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
PCF   10	Enterprise Value			269	311	307	306
NeYsided (1976) (2016)							
Fig.   1988							
Prime (CNY)   128							
Possible (Company)   Possibl							
PASS	P/B excl. GW (x)			1.28	0.94	0.87	0.76
Publisheriator precent							
Patron Front Post (1967)   Sales							
Sales         412         525         690         602         697           BETICAT         468         56         69         60         65           Depreciation         78         9         9         79         700         100 <td></td> <td></td> <td></td> <td>3.7</td> <td>3.2</td> <td>0.1</td> <td>3.0</td>				3.7	3.2	0.1	3.0
BIDDA							
Demonstrations							
Published EIFT   38 8   48 8   59   50   55   55   55   55   55   55							
Published EBT   1988	•						
Corporate To Ken tomore dequity-accounted companies         0.04         0.08         8.6         1.12         1.06           Profit foss of discontinued activities (after tax)         0.0							
Net nonce of equity-accounted companies   0.0							
Profit Does of discontinued activities (after tax)         0.0         2.28         0.0         0.0         0.0           Minority interests         1.0         1.6         1.0         1.0         1.0         1.0           Activitiation for the state of the s	· ·						
Minority Interests   1.10							
Aguited stributable net profit   318   312   40,1   737   30,8     BALINIC STRIFT (FO)   1222   1222   1223   1226   1226     Cookelli   488   47.5   47.5   47.5   47.5   47.5     For profit profit policy sests   488   47.5   47.5   47.5   47.5     For profit profit policy sests   488   47.5   47.5   47.5   47.5     For profit profit policy sests   488   47.5   47.5   47.5   47.5     For profit profit policy sests   48.0   87.0   18.0   14.0   11.2   7.8     For profit profit policy sests   47.5   18.0   17.0   18.0     For profit profit policy sests   47.5   18.0   17.0   17.0     For profit profit policy sests   47.5   47.5   47.5   47.5     For profit profit policy sests   47.5   47.5   47.5   47.5     For profit profit policy sests   47.5   47.5   47.5     For profit profit policy sests   47.5   47.5   47.5     For profit profit profit policy sests   47.5   47.5     For profit profit profit policy sests   47.5   47.5     For profit profit profit profit profit policy sests   47.5   47.5     For profit pr							
PALANES   1972   1972   1974   1975   1976   1972							
Goodwill         438         47,5         47,5         47,5         47,5         47,5         18,0         22,7         44,5         18,0         22,7         44,5         18,0         11,0         22,7         44,5         17,8         18,0         11,0         11,0         17,1         77,0							
Ober integlible kasets         640         89.2         91.0         92.7         94.5           Excipation kasets         330         73.4         71.9         71.6           Incapilal kasets         380         73.6         72.4         71.9         71.6           Continuary shareholders equity         80.5         132         21.4         23.3         22.5           Shareholders equity         81.6         81.5         21.7         23.3         22.8           Shareholders equity         81.6         13.5         21.7         23.3         22.8           Shareholders equity         81.6         13.5         21.7         23.3         22.8           Shareholders equity         81.6         13.5         21.7         23.3         22.8           New current provisions         81.6         13.5         21.7         23.3         22.8           Research Text         81.6         12.7         12.5         12.8 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
WCR         MCR         75.0         71.5         71.5           Financial sacts         11.7         20.0         12.2         12.1         23.2         22.5           Minority interests         11.1         32.2         21.2         23.2         25.2           Shareholders equity         81.6         13.5         21.7         23.2         22.5           Shareholders equity         81.6         13.5         21.7         23.2         22.5           Shareholders equity         81.6         13.5         21.7         23.2         22.5           Non-current provisions         11.0         13.6         13.6         14.7         14.6         14.6         14.7         14.6         14.6         14.7         14.6         14.7         14.6         14.7         14.6         14.7         14.7         14.7         14.7         14.7         <							
Financialisasets							
Ordinary shareholders equity         805         112         212         230         225           Minority interests         11         32         42         40         41         42         42         42         42         42         <							
Minority interests gaily							
Non-current provisions							
Net ole							
CASHEMOSTATEMENT (cm)         12/23         12/26<							
BITDA							
Interests taxes         6.6         13.7         1.0         2.5         4.0           Others         88.7         24.3         3.37         20.3         22.6           Operating Cash flow         104.1         5.79         31.8         38.7         20.3         38.7           CAPEX         210         81.1         38.7         20.3         38.7         20.3         38.7           CAPEX         210         81.0         48.8         38.8         38.8         38.7         20.3         38.7         20.3         38.7         20.3         38.7         20.3         38.7         20.3         38.7         20.3         38.7         20.3         38.7         20.3         38.8 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
Others         88.7         24.3         -8.26         -22.6           Operating Cash flow         104 1         5.79         31.8         38.7         38.7           CAPEX         -21.0         -8.1         8.2         1.83         38.4           Free cash-flow         83.0         44.8         23.5         30.4         30.0           Chegistrons/disposals         -9.8         44.8         -0.0         0.0							
Operating Cash flow         104.1         57.9         31.8         38.7         38.8           CAPEX         221.0         84.1         28.2         8.3         8.4           Free cash-flow         83.0         49.8         23.5         30.4         30.3           Acquisitions/ disposals         58.8         48.4         40.0         0.0         0.0           Dividends         0.0         0.0         0.0         0.0         0.0         0.0           Net capital increase         40.0         0.0         0.0         0.0         0.0         0.0           Charge in et cash         40.0         <							
CAPEY         2.10         8.1         -8.2         -8.3         -8.4           Free cash-flow         38.0         49.8         23.5         30.4         30.3           Acquisitions/disposals         -58.8         -48.4         -40.0         0.0         0.0           Dividends         0.0         0.0         0.0         0.0         0.0           Otterapitationese         0.0         -1.2         16.5         -15.5         -18.5           Change innet cash         25.3         32.4         10.5         -15.5         -18.5           Comment cash         12/2         12/2         12/25         12/26         12/25         -18.5           Sales growth         12.3         12/2         12/25         12/26         12/25         12/26         12/25         12/26         12/25         12/26         12/25         12/26         12/25         12/26         12/25         12/26         12/25         12/26         12/25         12/26         12/26         12/26         12/26         12/26         12/26         12/26         12/26         12/26         12/26         12/26         12/26         12/26         12/26         12/26         12/26         12/26         12/26							
Acquisitions / disposals         -58.8         -48.4         -40.0         0.0         0.0           Dividends         0.0         <							
Dividends         00         0.0         0.0         0.0         0.0           Net capital increase         0.0							
Net capital increase         0.0							
Others         4.0         -1.2         1.65         -1.55         -1.85           Change innet cash         25.3         -3.21         -1.05         4.3         1.72           CROWTH MARGINS PRODUCTIVITY         12/28         12/							
Change in net cash         25.3         -32.1         -10.6         4.3         1.2           CROWITH MARGINS PRODUCTIVITY         12/28         12/29         12/24         12/25         12/26							
Sales growth         -         21.4%         31.6%         16.2%         4.5%           Lf sales growth         -							
Lflasersowth         - <t< td=""><td></td><td></td><td>12/23</td><td></td><td></td><td></td><td></td></t<>			12/23				
Current EBIT growth         - 17.7%         29.6%         - 15.0%         9.9%           Growth in adjusted EPS         - 17.2%         28.7%         31.9%         12.7%           Net margin         5.9%         5.8%         3.4%         3.7%           EBITDA margin         10.8%         10.6%         10.0%         4.7%         5.8%           Current EBIT margin         9.9%         8.7%         8.6%         6.2%         6.6%           CAPEX/ Sales         -9.9%         14.0%         10.0%         9.0%         8.7%         1.0%         9.0%         8.7%         1.0%         9.0%         8.7%         1.0%         9.0%         8.6%         6.0%         6.0%			- -	21.4%	31.6%	16.2%	4.5%
Growth in adjusted EPS         - 17.2%         28.7%         3.1%         12.7%           Net margin         7.4%         5.9%         5.8%         3.4%         3.7%           EBITDA margin         10.6%         10.6%         10.0%         4.7%         7.8%           Current EBIT margin         9.0%         8.7%         8.6%         6.2%         6.6%           CAPSLY Sales         4.9%         1.1.5%         1.1.2%         1.1.0%         1.0%         6.6%           WCR / Sales         4.9%         1.1.5%         1.1.2%         1.1.2%         1.1.0%         1.0%         6.6%           WCR / Sales         4.0%         1.0.4%         1.0.6         1.0%         1.0%         1.0%         1.0%         1.0%         1.0%         1.0%         1.0%         1.0%         1.0%         1.0%         1.0%         3.0%			-	17.7%	29.6%	-15.6%	9.9%
EBITDA margin         10.8%         10.6%         10.0%         7.5%         7.8%           Curret EBIT margin         9,0%         8,7%         8.6%         6.2%         6.6%           CAPEX/Sales         4.9%         1,1%         1,12%         1,1%	Growth in adjusted EPS			-17.2%	28.7%	-31.9%	
Current EBIT margin         9.0%         8.7%         8.6%         6.6%           CAPEX/ Sales         -4.9%         -1.5%         -1.2%         -1.0% <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
CAPEX/Sales         -1.9%         -1.2%         -1.2%         -1.0%							
WCR / Sales         8.8%         14.0%         10.6%         9.0%         8.5%           Tax Rate         -1.1%         2.2%         17.3%         30.0%         30.0%           Normative tax rate         30.0%         30.0%         30.0%         30.0%         30.0%           Asset Turnover         -         2.7         3.0         30.0%         3.0%           ROCE post-tax (normative tax rate)         -         2.7         18.3%         15.6%         17.3%           ROE post-tax (normative tax rate)         -         2.1%         29.3%         23.1%         19.6%         22.0%           ROE         -         2.93         23.2%         12.3%         12.4%           DEBT RATIOS         12/23         12/24         12/25         12/25         12/27           Gearing         84         74         51         46         39%           Net Obbt / Market Cap         84         74         51         50         50         50         30           EBITDA / net financial charges         73         59         7.2         62         6.8							
Normative tax rate         30.0%         20.0%         20.2%         12.2%         12.2%         20.2%         12.2% <td>WCR / Sales</td> <td></td> <td>8.8%</td> <td>14.0%</td> <td>10.6%</td> <td>9.0%</td> <td>8.5%</td>	WCR / Sales		8.8%	14.0%	10.6%	9.0%	8.5%
Asset Turnover         -         2.7         3.0         3.6         3.8           ROCE post-tax (normative tax rate)         -         16.7%         18.3%         15.6%         17.3%           ROCE post-tax (normative tax rate)         -         2.1,9%         23.1%         19.8%         22.0%           ROE         -         2.93         23.2%         12.2%         12.4%           DEBT RATIOS         12/23         12/24         12/25         12/26         12/26           Gearing         84         74%         51%         46%         30%           Net Debt /Market Cap         8         74%         51.5         5.05         0.53         0.53           Ebit DA / net financial charges         147         18.1         1.61         1.78         1.63							
ROCE post-tax (normative tax rate)         1 6.7%         18.3%         15.6%         17.3%           ROCE post-tax hors GW (normative tax rate)         - 21.9%         23.1%         19.8%         22.0%           ROE         - 29.3%         23.2%         12.3%         12.4%           DED TAX TOS         12/23         12/25         12/25         12/27c           Gearing         84%         74%         51%         46%         39%           Net Debt / Market Cap         84%         74%         16.1         16.1         1.78         1.63           EBITDA / net financial charges         7.3         5.9         7.2         6.2         6.8			30.0%				
ROCE post-tax hors GW (normative tax rate)         -         21,9%         23.1%         19.8%         22.0%           ROE         -         29.3%         23.2%         12.3%         12.4%           DEBT RATIOS         12/23         12/24         12/25         12/26         12/27e           Gearing         84%         74%         51%         46%         39%           Net Debt / Market Cap         0.60         0.55         0.53         0.53           Net debt / EBITDA         1.47         1.81         1.61         1.78         1.63           EBITDA / net financial charges         7.3         5.9         7.2         6.2         6.8			<u>=</u>				
DEBT RATIOS         12/23         12/24         12/25e         12/26e         12/27e           Gearing         84%         74%         51%         46%         37%           NET DEBT / Market Cap         0.5         0.5         0.5         0.5         0.5           Net debt / EBITDA         1.47         1.81         1.61         1.78         1.63           EBITDA / net financial charges         7.3         5.9         7.2         6.2         6.8	ROCE post-tax hors GW (normative tax rate)		-	21.9%	23.1%		
Gearing         84%         74%         51%         46%         39%           Net Debt / Market Cap         0.60         0.55         0.53         0.53           Net debt / EBITDA         1.47         1.81         1.61         1.78         1.63           EBITDA / net financial charges         7.3         5.9         7.2         6.2         6.8							
Net Debt / Market Cap         0.60         0.55         0.53         0.53           Net debt / EBITDA         1.47         1.81         1.61         1.78         1.63           EBITDA / net financial charges         7.3         5.9         7.2         6.2         6.8							
Net debt / EBITDA         1.47         1.81         1.61         1.78         1.63           EBITDA / net financial charges         7.3         5.9         7.2         6.2         6.8			04%				
			1.47				
Sources: UDDU BHF Securities, SIX			7.3	5.9	7.2	6.2	6.8
	Sources: ODDO BHF Securities, SIX						

Thursday, May 1, 2025



## Valuation method

Our target prices are established on a 12-month timeframe and we use three valuation methods to determine them. First, the discounting of available cash flows using the discounting parameters set by the Group and indicated on ODDO BHF' website. Second, the sum-of-the-parts method based on the most pertinent financial aggregate depending on the sector of activity. Third, we also use the peer comparison method which facilitates an evaluation of the company relative to similar businesses, either because they operate in identical sectors (and are therefore in competition with one another) or because they benefit from comparable financial dynamics. A mixture of these valuation methods may be used in specific instances to more accurately reflect the specific characteristics of each company covered, thereby fine-tuning its evaluation.

## • Sensitivity of the result of the analysis/ risk classification:

The opinions expressed in the financial analysis are opinions as per a particular date, i.e. the date indicated in the financial analysis. The recommendation (cf. explanation of the recommendation systematic) can change owing to unforeseeable events which may, for instance, have repercussions on both the company and on the whole industry.

### · Our stock market recommendations

Our stock market recommendations reflect the RELATIVE performance expected for each stock on a 12-month timeframe. Outperform: performance expected to exceed that of the benchmark index, sectoral (large caps) or other (small and mid caps). Neutral: performance expected to be comparable to that of the benchmark index, sectoral (large caps) or other (small and mid caps). Underperform: performance expected to fall short of that of the benchmark index, sectoral (large caps) or other (small and mid caps).

- The prices of the financial instruments used and mentioned in this document are the closing prices.
- · All publications by ODDO BHF concerning the companies covered and mentioned in this document are available on the research site: www.securities.oddobhf.com/#disclaimer.

Recommendation and target price changes history over the last 12 months for the company analysed in this report				
Date	Reco	Price Target (EUR)	Price (EUR)	Analyst
27/11/24	Outperform	13.50	7.20	Klaus Breitenbach
23/07/24	Outperform	12.50	8.64	Klaus Breitenbach

In accordance with Article 20 of European Regulation No. 596/2014 (Market Abuse Regulation), a list of all recommendations on any financial instrument or issuer that have been disseminated over the past twelve months is available by clicking on the following link www.securities.oddo-bhf.com/#disclaimer.

Recommendation split				
		Outperform	Neutral	Underperform
Our whole coverage	(770)	52%	40%	8%
Liquidity providers coverage	(119)	48%	43%	9%
Research service coverage	(68)	57%	35%	7%
Investment banking services	(45)	69%	29%	2%

Risk of conflict of interest:	
Investment banking and/or Distribution	If yes, specify the name of the issuers concerned
Has ODDO BHF SCA or its affiliates managed or co-managed in the last 12 months a public offering of securities for the subject company/ies?	No
Has ODDO BHF SCA or its affiliates received compensation for other investment banking services from the subject company/ies in the last 12 months or expects to receive or intends to seek compensation for other investment banking services from the subject company/ies in the last 12 months?	No
Research contract between ODDO group & the issuer	If yes, specify the name of the issuers concerned
Have ODDO BHF SCA or its subsidiary ABN AMRO – ODDO BHF B.V. and the subject company/ies agreed that ABN AMRO - ODDO BHF B.V. or one of its parent companies will produce and disseminate investment recommendations on the subject company/ies as a service to the the subject company/ies?	No
Liquidity provider agreement and market-making	If yes, specify the name of the issuers concerned
At the date of the distribution of this report does ODDO BHF SCA or its affiliates act as a market maker or has ODDO BHF SCA or its affiliates signed a liquidity provider agreement with the subject company/ies?	No

Significant equity stake	If yes, specify the name of the issuers concerne
Does ODDO BHF SCA or its subsidiary ABN AMRO – ODDO BHF B.V. own 1% or more of any class of common equity securities of the subject company/ies?	No
One or more affiliates of ODDO BHF SCA other than ABN AMRO – ODDO BHF B.V. from time to time may own 1% or more of a class of common equity securities of the subject company/ies.	No
Does ODDO BHF SCA or its subsidiary ABN AMRO – ODDO BHF B.V. own a net long or short position of 0.5% or more of any class of common equity securities of the subject company/ies?	No
Does the subject company beneficially own 5% or more of any class of common equity of ODDO BHF SCA or its subsidiary ABN AMRO – ODDO BHF B.V.?	No

## Disclosure to Company

Thursday, May 1, 2025



Has the financial analysis been sent to the issuer for verification prior to publication?	No
Have any modifications been made to the conclusions of the analysis following its verification by the issuer?	No
Additional material conflicts	
Is ODDO BHF SCA or its affiliates aware of any additional material conflict of interest?	No
Personal conflicts of interest	
Do you buy or sell financial instruments from the issuer(s) concerned by this financial analysis?	No
Have those responsible for the drafting of the present document received remuneration directly linked to investment firm service transactions or any other kind of transaction they carry out or any trading commissions they or any legal person who is part of the same group receive?	No

 $Statement\ of\ conflict\ of\ interests\ of\ all\ companies\ mentioned\ in\ this\ document\ may\ be\ consulted\ on\ ODDO\ BHF:\ www.securities.oddo-bhf.com/\#disclaimer.$ 

Thursday, May 1, 2025

### Disclaimer:



## Disclaimers for Distribution by ODDO BHF SCA to Non-United States Investors:

This research publication is produced by the Corporates & Markets division of ODDO BHF SCA ("ODDO"), which is licensed by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the Autorité des Marchés Financiers ("AMF").

The research, when distributed outside of the U.S., is intended exclusively for non-U.S. customers of ODDO and cannot be divulged to a third-party without prior written consent of ODDO. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. This research has been prepared in accordance with regulatory provisions designed to promote the independence of investment research. "Chinese walls" (information barriers) have been implemented to avert the unauthorized dissemination of confidential information and to prevent and manage situations of conflict of interest. This research has been prepared in accordance with French regulatory provisions designed to promote the independence of investment research. The recommendation presented in this document is reviewed and updated at least quarterly following each Quarterly Report published by the issuer that is the subject of this Research Report.

At the time of publication of this document, ODDO and/or one of its subsidiaries may have a conflict of interest with the issuer(s) mentioned. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such. Past performances offer no guarantee as to future performances. All opinions expressed in the present document reflect the current context which is subject to change without notice. The views expressed in this Research Report accurately reflect the analyst's personal views about the subject securities and/or issuers and no part of his compensation was, is, or will be directly or indirectly related to the specific views contained in the Research Report. This Research Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice.

This Research Report is for institutional investors only. It may not contain information necessary for others to make investment decisions. Consult your financial adviser or an investment professional if you are not an institutional investor.

## Disclaimers for Distribution by ODDO BHF New York Corporation to United States Investors:

This Research Report is produced by ODDO BHF Corporates & Markets, a division of ODDO. This research is distributed to U.S. investors exclusively by ODDO BHF New York Corporation ("ONY"), MEMBER: FINRA/SIPC, and is intended exclusively for U.S. customers of ONY and cannot be divulged to a third-party without prior written consent of ONY. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. This research has been prepared in accordance with regulatory provisions designed to promote the independence of investment research. "Chinese walls" (information barriers) have been implemented to avert the unauthorized dissemination of confidential information and to prevent and manage situations of conflict of interest. This research has been prepared in accordance with French regulatory provisions designed to promote the independence of investment research. The recommendation presented in this document is reviewed and updated at least quarterly following each Quarterly Report published by the issuer that is the subject of this Research Report.

At the time of publication of this document, ODDO, and/or one of its subsidiaries may have a conflict of interest with the issuer(s) mentioned. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such. Past performances offer no guarantee as to future performances. All opinions expressed in the present document reflect the current context which is subject to change without notice. The views expressed in this Research Report accurately reflect the analyst's personal views about the subject securities and/or issuers and no part of his compensation was, is, or will be directly or indirectly related to the specific views contained in the Research Report. This Research Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice.

This Research Report is for institutional investors only. It may not contain information necessary for others to make investment decisions. Consult your financial adviser or an investment professional if you are not an institutional investor.

Disclosures Required by United States Laws and Regulations:

Rule 15a-6 Disclosure: Under Rule 15a-6(a)(3), any transactions conducted by ODDO, and/or one of its subsidiaries with U.S. persons in the securities described in this foreign research must be effected through ONY. As a member of FINRA, ONY has reviewed this material for distribution to U.S. persons as required by FINRA Rules 2241(h) applicable to dissemination of research produced by its affiliate ODDO.

## FINRA Disclosures:

- Neither ONY, ODDO, nor ODDO BHF Corporates & Markets beneficially owns 1% or more of any class of common equity securities of the subject company.
- The research analyst of ODDO BHF Corporates & Markets, at the time of publication of this research report, is not aware, nor does he or she know or have reason to know of any actual, material conflict of interest of himself or herself, ODDO, ODDO BHF Corporates & Markets or ONY, except those mentioned in the paragraph entitled "Risks of Conflicts of Interest"
- ODDO BHF Corporates & Markets or ODDO may receive or seek compensation for investment banking services in the next 3 months from the subject company of this Research Report, but ONY would not participate in those arrangements.
- Neither ONY, ODDO, ODDO BHF Corporates & Markets has received compensation from the subject company in the past 12 months for providing investment banking services except those mentioned in the paragraph of "Risks of Conflict of Interest"."
- Neither ONY, ODDO, ODDO BHF Corporates & Markets has managed or co-managed a public offering of securities for the subject company in the past 12 months except those mentioned in the paragraph of "Risk of Conflict of Interest".
- ONY does not make (and never has made) markets and, accordingly, was not making a market in the subject company's securities at the time that this research report was published.

## Regulation AC:

ONY is exempt from the certification requirements of Regulation AC for its distribution to a U.S. person in the United States of this Research Report that is prepared by an ODDO BHF Corporates & Markets research analyst because ODDO has no officers or persons performing similar functions or employees in common with ONY and ONY maintains and enforces written policies and procedures reasonably designed to prevent it, any controlling persons, officers or persons performing similar functions, and employees of ONY from influencing the activities of the third party research analyst and the content of research reports prepared by the third party research analyst.

Contact Information of firm distributing research to U.S. investors: ODDO BHF New York Corporation, MEMBER: FINRA/SIPC, is a wholly owned subsidiary of ODDO BHF SCA; Louis paul ROGER, President (louis-paul.roger@oddo-bhf.com) 150 East 52nd Street New York, NY 10022 646-286-2137.

Statement of conflict of interests of all companies mentioned in this document may be consulted on Oddo BHF research site.